CD276 molecule (B7-H3) (CD276)

CD276, widely known as B7-H3, is a type I transmembrane glycoprotein belonging to the B7 family of immune checkpoint molecules (UniProt Q5ZPR3). It plays a complex role in the immune system, exhibiting both co-stimulatory and co-inhibitory properties on T-cell activation, though its predominant role in the tumor microenvironment is immunosuppressive (PMID: 31110339). B7-H3 is highly overexpressed in numerous solid tumors—including neuroblastoma, prostate cancer, and lung cancer—while its expression in normal healthy tissues is relatively low, making it a compelling target for precision oncology (PMID: 33431109). Current therapeutic strategies include monoclonal antibodies that trigger immune-mediated cell killing, antibody-drug conjugates (ADCs) that utilize the protein for selective delivery of chemotherapy, and chimeric antigen receptor (CAR) T-cell therapies (ClinicalTrials.gov NCT04145622). Additionally, research into B7-H3 mRNA involves its use in dendritic cell vaccines to prime the immune system or the use of RNA interference (siRNA) to silence its expression in malignant cells (PMID: 25609153). This multi-modal targeting approach highlights the versatility of B7-H3 as a biomarker and therapeutic focal point in modern oncology.

Other names

B7-H3B7H34Ig-B7-H3Costimulatory moleculeCD276 antigen

Monoclonal antibody-mediated antibody-dependent cellular cytotoxicity (ADCC), antibody-drug conjugate (ADC) delivery of cytotoxic payloads, and chimeric antigen receptor (CAR) T-cell redirection to tumor cells.